Opinion|Videos|March 22, 2024
Muscle-Invasive Bladder Cancer Treatment Practices
Karine Tawagi, MD, and Sia Daneshmand, MD, offer comprehensive insights on treatment practices for patients with muscle-invasive bladder cancer.
Advertisement
Advertisement
Related to this article
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5